These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 16870750)

  • 1. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.
    Nuermberger E; Rosenthal I; Tyagi S; Williams KN; Almeida D; Peloquin CA; Bishai WR; Grosset JH
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2621-5. PubMed ID: 16870750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.
    Tasneen R; Tyagi S; Williams K; Grosset J; Nuermberger E
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3664-8. PubMed ID: 18694943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.
    Tasneen R; Li SY; Peloquin CA; Taylor D; Williams KN; Andries K; Mdluli KE; Nuermberger EL
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5485-92. PubMed ID: 21930883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.
    Tyagi S; Nuermberger E; Yoshimatsu T; Williams K; Rosenthal I; Lounis N; Bishai W; Grosset J
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2289-93. PubMed ID: 15917523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
    Nuermberger E; Tyagi S; Tasneen R; Williams KN; Almeida D; Rosenthal I; Grosset JH
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1522-4. PubMed ID: 18285479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
    Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL
    PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
    Rosenthal IM; Tasneen R; Peloquin CA; Zhang M; Almeida D; Mdluli KE; Karakousis PC; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4331-40. PubMed ID: 22664964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.
    Jindani A; Doré CJ; Mitchison DA
    Am J Respir Crit Care Med; 2003 May; 167(10):1348-54. PubMed ID: 12519740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models.
    Lenaerts AJ; Gruppo V; Marietta KS; Johnson CM; Driscoll DK; Tompkins NM; Rose JD; Reynolds RC; Orme IM
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2294-301. PubMed ID: 15917524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bactericidal action of pulsed exposure to rifampicin, ethambutol, isoniazid & pyrazinamide on Mycobacterium tuberculosis in vitro.
    Paramasivan CN; Herbert D; Prabhakar R
    Indian J Med Res; 1993 Jul; 97():145-50. PubMed ID: 8406638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sterilizing Activity of Pyrazinamide in Combination with First-Line Drugs in a C3HeB/FeJ Mouse Model of Tuberculosis.
    Lanoix JP; Betoudji F; Nuermberger E
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1091-6. PubMed ID: 26643352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of childhood tuberculosis with a six month directly observed regimen of only two weeks of daily therapy.
    Al-Dossary FS; Ong LT; Correa AG; Starke JR
    Pediatr Infect Dis J; 2002 Feb; 21(2):91-7. PubMed ID: 11840073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bactericidal therapy in patients with tuberculosis].
    Krasnov VA; Ursov IG
    Probl Tuberk Bolezn Legk; 2004; (3):21-6. PubMed ID: 15338895
    [No Abstract]   [Full Text] [Related]  

  • 17. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis. First report.
    Am Rev Respir Dis; 1978 Aug; 118(2):219-28. PubMed ID: 100029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
    Williams K; Minkowski A; Amoabeng O; Peloquin CA; Taylor D; Andries K; Wallis RS; Mdluli KE; Nuermberger EL
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3114-20. PubMed ID: 22470112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.
    Iacobino A; Giannoni F; Pardini M; Piccaro G; Fattorini L
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.